ArticleJournal, genetic engineering & biotechnology2025
Whole-genome sequencing and biofilm gene characterization in multidrug-Resistant Staphylococcus aureus clinical strains.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Genomic insights into multidrug resistance and virulence of methicillin-resistantFrontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus is known as a significant contributor to a variety of severe, life-threatening illnesses. Infectious diseases associated with biofilm-producing S. aureus can lead to a substantial increase in morbidity and mortality rates. This study aimed to characterize the whole genomes of eight clinically multidrug-resistant S. aureus strains isolated from several types of human infections sites from Hail Hospital, Saudi Arabia. Biofilm production was evaluated using Congo-red agar plates (CRA), polystyrene microtiter plate technique (MtP), and adherence to human epithelial cells (Hep 2). Additionally, adhesion to abiotic surface (Polyethylene, glass, stainless steel) was assessed using scanning electron microscopy (SEM). Then whole genome sequencing was conducted for all strains to analyze the virulome, resistome and phylogenome using different bioinformatic tools. Our results revealed that all S. aureus strains were slime producer on CRA plates with pigmented colonies (black and nearly black morphotypes) and were also able to form biofilm on the surface of several materials with different degrees. All tested strains adhere to Hep2 cell lines with a percentage of infected cells ranging from 45.0 % ± 0.078 to 92.0 % ± 0.022, and a total number of S. aureus/100 cells varying from 5.11 ± 2.14 (Strain S22) to 20.25 ± 5.15 (Strain S14). These results were correlated with those obtained from genome annotation highlighting that all multidrug resistant and biofilm-producing S. aureus strains harbored four ica genes (icaA, icaB, icaC, icaD) and their regulator icaR), clumping factor A and B (clfA and clfB genes), fibronectin binding proteins (fnbA in all strains and fnbB in 87.5 % of tested strains), elastin binding protein (ebps gene), extracellular adherence protein (Eap), staphylococcal protein A (spa gene), and Ser-Asp rich fibrinogen-binding proteins (sdrC). Most of the studied strains contained six to ten genomic islands associated with virulence factors, phage proteins, transcriptional regulators, insertion sequences and antimicrobial resistance genes. The study reported the presence of key adhesion-related genes underscores the colonization potential and pathogenicity in our strains. Additionally, the identification of multiple genomic islands associated with virulence and antimicrobial resistance highlights the need for vigilant monitoring in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.